Zouxiang Chen on Muck Rack

Zouxiang Chen

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zouxiang

Contact Zouxiang, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Anti-PD-1 antibody combined with P-GEMOX chemotherapy versus P-GEMOX chemotherapy with or without autologous stem-cell transplantation for previously untreated advanced natural killer/T cell lymphoma: a retrospective cohort study

|
By Qihua Zou, Yi Cao, Liang Wang, Wuping Li, Qingsong Yin, Yudan Wu, Hongmei Jing, Zhigang Peng, Xiuhua Sun, Jun Rao, Ying Chen, Hongyu Zhang, Dongfeng Zeng, Bingzong Li, Ying Zhao, Xudong Zhang, Yuchen Zhang, Yan Gao, Bing Bai, Yi Xia, Yu Fang, Man Nie, Xiaojie Fang, Shenrui Bai, Huiqiang Huang, Qingqing Cai, Jun Cai, Zouxiang Chen
| Nature Verified
Abstract We evaluated the effectiveness of adding anti-PD-1 antibody to P-GEMOX regimen in previously untreated advanced-stage natural killer/T-cell lymphoma (NKTCL) compared to P-GEMOX alone or with autologous stem cell transplantation (ASCT). 418 patients (135 and 283 in the immunochemotherapy and chemotherapy groups, respectively) were analyzed from 15 Chinese centers (2014–2023). The median follow-up was 40.7 months.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified